Thirty years ago, we knew very little about Alzheimer's disease. Since then, scientific research, supported by the National Institute on Aging and other components of the National Institutes of Health, the Alzheimer's Association, and other organizations has led to important advances in our knowledge about Alzheimer's disease and to the development of promising new drugs and treatment strategies. Today, scientists are investigating many approaches to treat, prevent, or cure Alzheimer's, with 91 drugs in clinical trials as of 2008 and more in the pipeline awaiting FDA approval to enter human testing.
Rapid advances in our knowledge about Alzheimer's disease have led to the development of promising new drugs and treatment strategies. However, before these new strategies can be used in clinical practice, they must be shown to work in people. Advances in prevention and treatment are only possible thanks to volunteers who participate in clinical trials.
At least 50,000 volunteers, both with and without Alzheimer's, are urgently needed to participate in more than 175 actively enrolling Alzheimer's disease trials and studies in the U.S. To reach that goal, at least half a million volunteers must be screened.
Learn more about participating in research by contacting the Alzheimer's Disease Education and Referral (ADEAR) Center of the National Institute on Aging (http://www.nia.nih.gov/Alzheimers/ResearchInformation/participateADresearch.htm) or call 1-800-438-4380.